by MyBioGate | Mar 31, 2018 | Uncategorized
“China’s changing pharmaceutical E- commerce market” is developed by Deloitte China Life Sciences and Health Care Industry, Technology, Media & Telecommunications Industry in collaboration with Deloitte Research. The technology of mobile Internet and...
by MyBioGate | Mar 31, 2018 | Uncategorized
The report “Excellence in Medical Affair: Recent trends in China Medical Affairs and Outcomes from China Medical Affairs Survey 2016” is developed by Deloitte China Life Sciences and Health Care Industry team. As the roles of Medical Affairs have become...
by MyBioGate | Mar 31, 2018 | Uncategorized
In a bid to move Chinese drug industry regulations closer to the US/European model, China’s FDA yesterday proposed significant changes to the nation’s Drug Administration Act. The widely expected move comes on the heels of instructions given two weeks ago by the...
by MyBioGate | Mar 31, 2018 | Uncategorized
China has recently announced several initiatives to reform its regulation of drugs and medical devices that could have a significant impact on pharmaceutical and medical device companies doing business in China. On October 8, 2017, the General Office of Chinese...
by MyBioGate | Mar 31, 2018 | Uncategorized
On 3 November 2017, the National Development and Reform Commission (“NDRC”), one of China’s key outbound investment regulatory bodies, has issued the Announcement on Seeking Public Comments on the Administrative Measures for Outbound Investment of Enterprises (Draft...
Recent Comments